Home » New Hair Loss Treatments Pipeline » Shiseido
Detailed information on the research project currently underway. We encourage you to bookmark these pages and check back often. Updates will be added periodically with new information on status, newly-released data, and clinical trial results. Back to New Hair Loss Research Pipeline
Shiseido acquired the exclusive license of RepliCel Life Sciences RCH-01 in the entire Asian region. They are conducting similar research, but on a different timeline and with separate trials. RCH-01 is an autologous cell therapy making use of dermal sheath cup cells isolated from the hair follicle to treat Androgenetic Alopecia.
These cells will be obtained from a small punch biopsy from the back of the subjects scalp. After this they will be replicated and injected back into the balding area of subjects scalp. The goal is to migrate the cellular and genetic traits of alopecia-immune hairs to hairs sensitive to the hair loss process.
Autologous Cell Transplantation Technology
08-11-16: Shiseido to Begin Cell Hair Regeneration Trial